Neurocrine shares jump 27% this year on strong sales and pipeline growth.
Neurocrine Biosciences saw its shares rise 27% in 2026, driven by over $800 million in Q1 product sales and a 44% growth in its key drug INGREZZA. The company reported around $200 million in net income and has a robust pipeline with 12 programs curre...
